Staar Surgical (STAA) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Staar Surgical (STAA) reported Q2 2025 revenue of $44.32 million, a 55.2% year-over-year decline, though it exceeded the Zacks Consensus Estimate by 6.63%. The company's EPS of -$0.07 significantly outperformed the -$0.56 consensus estimate. Geographic sales were mixed, with a notable 91.6% year-over-year decline in China sales, despite exceeding analysts' very low expectations for that region. While STAA shares have surged nearly 60% over the past month, the stock currently holds a Zacks Rank #4 (Sell), suggesting potential near-term underperformance.

Analysis

Staar Surgical's Q2 2025 results present a conflicting picture, characterized by significant beats on heavily revised-down estimates alongside a severe year-over-year deterioration in business fundamentals. The company reported revenue of $44.32 million, a 55.2% decline from the prior year, and an EPS of -$0.07, down from $0.33. While these figures surpassed consensus estimates for revenue and EPS by 6.63% and 87.5% respectively, the underlying geographic sales data reveals critical weaknesses. Most notably, sales in China collapsed by 91.6% year-over-year to $5.3 million, and 'Other International' sales fell 10.6%. Although the China result significantly exceeded the very low analyst estimate of $0.96 million, the magnitude of the annual decline points to a major market disruption. Positive contributions from Japan (+10.4% YoY) and the U.S. (+4.4% YoY) were insufficient to offset these declines. Despite this operational weakness, the stock has rallied 59.8% over the past month, a move that appears disconnected from the fundamental trends and at odds with its current Zacks Rank #4 (Sell) rating, which suggests potential near-term underperformance.

Key Decisions for Investors

• Investors should treat the stock's recent 59.8% rally with caution, as it is sharply disconnected from the severe 55.2% year-over-year revenue decline and the collapse in the China market.
• The 91.6% plunge in China sales is a critical red flag, and future performance will heavily depend on whether this market can be stabilized or if this represents a permanent impairment.
• Despite the significant beat on EPS and revenue estimates, the negative year-over-year fundamentals and the official Zacks #4 (Sell) rating suggest that maintaining or initiating long positions carries substantial risk.